HLA micropolymorphisms restrict neoantigen conformational adaptability, dictating T cell receptor recognition
Background
The adaptive immune system relies on T cell receptors (TCRs) recognizing specific peptide fragments presented by Major Histocompatibility Complex (MHC) proteins. While the impact of major MHC polymorphisms on peptide binding and selection is well-understood, the subtle effects of micropolymorphisms within closely related MHC supertypes on immune recognition remain largely unknown. This gap in knowledge hinders the precise design of antigen-specific immunotherapies and our understanding of how T cells differentiate between similar antigens, especially in contexts like cancer neoantigens or autoimmune diseases where subtle differences can be critical.
Study Design
Researchers investigated the mechanism by which two micropolymorphisms distinguishing HLA-A*03:02 from HLA-A*03:01 govern TCR specificity. Building on prior observations that TCRs specific for a public PIK3CA oncogenic neoantigen restricted by HLA-A*03:01 failed to recognize the same epitope presented by HLA-A*03:02, they conducted a detailed mechanistic study. The team focused on comparing the peptide presentation and TCR interaction dynamics of these two HLA-A3 superfamily members. Their approach involved analyzing the conformational ensemble of the neoantigen within the HLA complex, rather than just static structures or peptide binding affinity, to pinpoint the molecular basis of differential TCR recognition.
Results
The study revealed that the two micropolymorphisms differentiating HLA-A*03:02 from HLA-A*03:01 prevent TCR binding not by altering the peptide's binding affinity or the static structure of the peptide/HLA complex. Instead, these subtle genetic variations fundamentally alter the conformational ensemble of the neoantigen, thereby preventing it from adopting a TCR-binding-permissive state. This effect is rooted in how the two polymorphic sites engage in a complex, cross-groove network of interactions with other covarying, evolutionarily coupled polymorphisms within the MHC-I molecule. This intricate network ultimately controls the conformational adaptability of the presented peptide.
The micropolymorphisms in
HLA-A*03:02specifically restrict the dynamic flexibility of thePIK3CAneoantigen, rendering it 'invisible' toTCRsthat would otherwise recognize it when presented byHLA-A*03:01.
Key Findings
- HLA-A*03:02 micropolymorphisms block
TCRbinding to aPIK3CAneoantigen. - Blockage occurs by altering neoantigen conformational adaptability, not static structure or binding.
- Polymorphic sites interact in a cross-groove network, controlling peptide/HLA complex flexibility.
- Polymorphism-dependent adaptability is an evolved feature of Class I
MHCproteins. - High-resolution
HLAtyping is crucial for effective antigen-specific immunotherapies.
Why It Matters
This research provides a critical mechanistic insight into how subtle HLA micropolymorphisms can profoundly impact TCR recognition, moving beyond simple peptide binding. For peptide users and biohackers interested in cancer immunotherapies or autoimmune modulation, this highlights the crucial role of high-resolution HLA typing in predicting therapeutic efficacy and potential off-target effects. The practical takeaway is that antigen-specific immunotherapies, including neoantigen vaccines or adoptive T cell therapies, must consider not just peptide presentation, but also the conformational dynamics dictated by specific HLA alleles. This finding suggests that a neoantigen effective in one patient with HLA-A*03:01 might be entirely ineffective in another with HLA-A*03:02, even if the peptide sequence is identical. This necessitates more precise patient stratification and personalized approaches in clinical translation.
hla
tcr
mhc-i
immunology
neoantigen
polymorphism